Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission

Mora, J; Castaneda, A; Gorostegui, M; Santa-Maria, V; Garraus, M; Munoz, JP; Varo, A; Perez-Jaume, S; Mane, S

Mora, J (corresponding author), Hosp St Joan Deu, Pediat Canc Ctr Barcelona, Barcelona, Spain.

PEDIATRIC BLOOD & CANCER, 2021; 68 (10):

Abstract

Background Naxitamab is a humanized anti-disialoganglioside (GD2) monoclonal antibody approved for treatment of bone/bone marrow refractory high-risk ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索